Oral Neuroactive Steroids

The modulation of GABA-A receptors by neuroactive steroids (e.g. zuranolone) might contribute to the pathophysiology of depression. Here, Dr. Andrew Cutler and Dr. Roger McIntyre review the data and results from clinical studies of the investigational drug under development, zuranolone. Zuranolone, an investigational oral neuroactive steroid with a novel mechanism of action as a positive allosteric modulator of GABA-A and is being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with major depressive disorder (MDD) and postpartum depression (PPD).
NEI Members can watch the full-length lecture, titled “New Approaches: Novel Receptor Science in Depression” here: nei.global/encore
Learn about upcoming NEI Meetings: nei.global/meetings
Stay updated with email alerts: nei.global/updates
Interested in Psychopharmacology? Check out the NEI Master Psychopharmacology Program: nei.global/mpp
Follow us on Facebook: nei.global/facebook
Follow us on LinkedIn: nei.global/linkedin
Follow us on X: nei.global/twitter
Follow us on Instagram: nei.global/instagram
🎙 Listen to NEI Podcast: nei.global/podcast
Copyright © Neuroscience Education Institute. All rights reserved.

[@Suitswonderland]

I know its not the case but the way its stated at 3:24 makes it almost seem like the only reason this drug is good is because its not a benzodiazepine but can be used instead of one, which would be a terrible criteria for a medicine, toxicity and other factors would be far more desirable but just the way it was said I think, or maybe the automatic needing too defend the compound from everyone without a education in medicine (and lots with).